Payment overview · 2025
General Payments
$432.75
22 reported records · 12 companies
Healthcare provider profile · identity verified
Michael Gary Ziegler, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABILENE, KS · NPI 1053872358
Verified facts
What the public records show
CMS Open Payments records show Michael Gary Ziegler, MD received $432.75 in general payments during 2025 across 22 reported records.
Corcept Therapeutics accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $85.96 | 19.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.77 | 10.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.87 | 9.9% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $40.35 | 9.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.25 | 9.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.47 | 8.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.11 | 7.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.27 | 7.0% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.75 | 5.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.01 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.42 | 4.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.52 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.75 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $85.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.77 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.87 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $40.35 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 47 |
| Omeprazole | Omeprazole | 246 | 48 |
| Lisinopril | Lisinopril | 239 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 38 |
| Gabapentin | Gabapentin | 164 | 32 |
| Furosemide | Furosemide | 152 | 28 |
| Metformin Hcl | Metformin Hcl | 146 | 30 |
| Losartan Potassium | Losartan Potassium | 136 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 44 |
| Celecoxib | Celecoxib | 119 | 29 |
| Jardiance | Empagliflozin | 118 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 21 |
| Potassium Chloride | Potassium Chloride | 92 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 27 |
| Montelukast Sodium | Montelukast Sodium | 78 | suppressed |
| Mirtazapine | Mirtazapine | 77 | 11 |
| Trazodone Hcl | Trazodone Hcl | 77 | 14 |
| Bupropion Xl | Bupropion Hcl | 71 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 21 |
| Ozempic | Semaglutide | 68 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 66 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 13 |
| Cephalexin | Cephalexin | 62 | 32 |
| Atenolol | Atenolol | 61 | suppressed |
| Pregabalin | Pregabalin | 59 | 16 |
| Meloxicam | Meloxicam | 57 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Eliquis | Apixaban | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Simvastatin | Simvastatin | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Alprazolam | Alprazolam | 43 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Prednisone | Prednisone | 42 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 13 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.75 · 22 records | Corcept Therapeutics | ABRYSVO, AREXVY, Auvelity, BEXSERO, CAPLYTA, EVENITY, Korlym, LEQVIO, MOUNJARO, PEDIARIX, PENMENVY, PREVNAR 20, PROLIA, Prolastin-C Liquid, REXULTI, SHINGRIX, SMARTVEST, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error